U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07644767) titled 'Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar Depression' on May 27.
Brief Summary: This study is testing a new oral ketamine treatment called KET-AD in adults with treatment-resistant bipolar depression (TRBD). The study will look at how safe and tolerable the treatment is, and whether it may help improve symptoms of depression when used together with a participant's usual treatment.
About 160 people will take part in the study. Participants will be randomly assigned (like flipping a coin) to receive either KET-AD or a placebo (a treatment with no active medicine). Neither the participant nor the study team will k...